42 citations
,
April 2021 in “JCI insight” Blocking JAK3 signaling can reverse hair loss from alopecia areata.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” OR-101 shows promise for treating alopecia areata by improving hair growth.
1 citations
,
January 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors effectively treat skin conditions and topical forms are safer.
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Particulate matter causes inflammation in hair cells, potentially harming hair growth.
3 citations
,
January 2015 in “Nasza Dermatologia Online” Some treatments for autoimmune hair loss work, but JAK inhibitors like tofacitinib are promising for regrowth.
December 2022 in “Revista Medicina Cutánea Ibero-Latino-Americana” JAK inhibitors help treat alopecia areata but have high recurrence after stopping.
277 citations
,
December 2019 in “Frontiers in Immunology” JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.
40 citations
,
June 2021 in “Clinical, cosmetic and investigational dermatology” JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
37 citations
,
January 2016 in “Drug design, development and therapy” Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.
16 citations
,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” A patient with complete hair loss regrew all her hair using tofacitinib.
11 citations
,
October 2018 in “Pediatric dermatology” Leflunomide and anthralin may effectively treat severe alopecia areata.
489 citations
,
November 2021 in “Signal Transduction and Targeted Therapy” The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
124 citations
,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
70 citations
,
October 2020 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.
51 citations
,
October 2019 in “Cells” Baricitinib reduces inflammation and improves cell health in premature aging cells.
17 citations
,
May 2019 in “BMJ Open” JAK/STAT inhibitors show promise for skin diseases but aren't yet approved.
9 citations
,
May 2023 in “Inflammation Research” New small molecule drugs show promise in treating complex skin diseases but need more safety research.
1 citations
,
March 2024 in “Signal transduction and targeted therapy” NF-κB signaling is crucial in many diseases and can be targeted for new treatments.
14 citations
,
April 2021 in “International journal of molecular sciences” Mesenchymal stem cells may help treat hair loss by improving hair cell growth and reducing inflammation.
290 citations
,
December 2017 in “Journal of The American Academy of Dermatology” Alopecia areata is an autoimmune condition causing hair loss, influenced by genetics, stress, and diet, and may be prevented by a high soy oil diet.
36 citations
,
January 2021 in “Scientific Reports” Key genes and pathways, including Wnt, NF-Kappa, and JAK-STAT, are crucial for starting Pashmina fiber growth in goats.
32 citations
,
April 2019 in “JAAD case reports” JAK inhibitors helped treat hair loss in two people with Down syndrome.
27 citations
,
September 2017 in “Archives of Dermatological Research” Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.
26 citations
,
January 2019 in “Expert Opinion on Investigational Drugs” New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
4 citations
,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
2 citations
,
September 2021 in “Curēus” Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
1 citations
,
January 2017 in “Springer eBooks” Understanding the immune-related causes of Alopecia Areata has led to potential treatments like JAK inhibitors.